Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics
Executive Summary
The last five years have seen an explosion in novel approaches to Parkinson’s disease.
You may also be interested in...
Deals of the Week Watches Parkinson’s In Prime Time
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.
Deals of the Week Watches Parkinson’s In Prime Time
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.